PeterIKarachunskiMD

Child Neurology • Minneapolis, MN

Associate Professor, Pediatric neurology University of Minnesota Medical School

Join to view full profile

Dr. Karachunski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karachunski's full profile

Already have an account?

Office
420 Delaware Street Se
Moos tower 13-240 MMC 295
Minneapolis, MN 55455
Phone+1 612-626-2499

Fax+1 612-273-0886

Education & Training

University of MinnesotaFellowship, Child Neurology, 2002 - 2005
University of MinnesotaResidency, Pediatrics, 2000 - 2003
Russian State Medical UniversityClass of 1987

Certifications & Licensure

MN State Medical License 2005 - 2025
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD) Start of enrollment: 2005 Dec 01
Unknown status
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping Start of enrollment: 2012 Apr 01
Unknown status
Finding the Optimum Regimen for Duchenne Muscular Dystrophy Start of enrollment: 2013 Jan 01
Completed
Phase 3
A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects Start of enrollment: 2013 May 01
Terminated
Phase 3
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Start of enrollment: 2017 Jul 06
Completed
Phase 3
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) Start of enrollment: 2018 Sep 25
Recruiting
Join now to see all

Publications & Presentations

PubMed

268 citations
Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study
Craig M. McDonald, Erik K Henricson, Richard T. Abresch, Tina Duong, Nanette C. Joyce
Lancet. 2017-11-22
19 citations
Truncating mutations in YIF1B cause a progressive encephalopathy with various degrees of mixed movement disorder, microcephaly, and epilepsy
Mohammed A. AlMuhaizea, Rawan Almass, Aljouhra AlHargan, Anoud Abdulmalik Albader, Eva Medico Salsench
Acta Neuropathologica. 2020-01-31
294 citations
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Craig M. McDonald, Craig Campbell, Ricardo Erazo Torricelli, Richard S. Finkel, Kevin M. Flanigan
Lancet. 2017-09-23

Journal Articles

TANGO2: Expanding the Clinical Phenotype and Spectrum of Pathogenic Variants
Jennifer N Dines, Heather C Mefford, Barbara Burton, Joline Dalton, Alice Basinger, Peter Karachunski, Can Ficicioglu, Katherine L Helbig, Nature

Press Mentions

Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 SkippingMay 26th, 2020
Toddler Who Got World’s Most Expensive Drug WalksFebruary 25th, 2020
Toddler with Fatal Muscle Condition ‘Recovers’ After $2m Infusion of World’s Most Expensive DrugFebruary 25th, 2020
Join now to see all